HLA-A*0201 & B2M & hTERT (ILAKFLHWL)

HLA-A*0201 & B2M & hTERT (ILAKFLHWL) Product List

  • Product Category

    Protein (3)

  • Product Status

    Launched (3)

  • Species

    Human (3)

  • Tag

    His Tag (2)His Tag & Avi Tag (1)

  • Conjugate

    APC Labeled (1)PE Labeled (1)Biotin-labeled (1)

HLA-A*0201 & B2M & hTERT (ILAKFLHWL) Background

hTERT (human Telomerase Reverse Transcriptase), the catalytic subunit of telomerase, maintains telomere length to drive tumor cells’ unlimited proliferation. It is highly expressed in ~85-90% of cancers but silenced in most normal somatic cells. The peptide ILAKFLHWL (from hTERT residues 540-548) acts as a tumor-specific antigen. It binds to MHC class I molecule HLA-A0201 to form a surface complex on tumors, activating cytotoxic T lymphocytes (CTLs). The Human HLA-A*0201 hTERT (ILAKFLHWL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and ILAKFLHWL peptide of the hTERT.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
JWATM-203JWATM-203; JWATM203Phase 2 ClinicalSuzhou Yaomingjunuo Biotechnology Co LtdCarcinoma, Hepatocellular
Details
SynOV1.1Phase 2 ClinicalBeijing Syngentech Co LtdSolid tumours; Carcinoma, Hepatocellular
Details
ET140203Phase 2 ClinicalEureka Therapeutics IncLiver Neoplasms; Hepatoblastoma; Carcinoma, Hepatocellular
Details
Alpha fetoprotein targeted T-cell therapy (Adaptimmune)AFP TCR (ADP-A2AFP); ADP-A2AFP; AFP TCR; AFPc332TPhase 1 ClinicalAdaptimmune LlcLiver Neoplasms
Details
HRYZ-T102HRYZ-T102Phase 1 ClinicalHengrui Yuanzheng (Shanghai) Biotechnology Co LtdSolid tumours; Carcinoma, Hepatocellular
Details
ET1402L1-CARTAFP/ET-1402; ET1402; ET-1402; AFP-CAR; ET-140202Phase 1 ClinicalEureka Therapeutics IncLiver Neoplasms; Carcinoma, Hepatocellular
Details
TAEST-1901TAEST-1901Phase 1 ClinicalXiangxue Life Science Technology (Guangdong) Co LtdLiver Neoplasms; Neoplasms
Details
ET1402L1-ARTEMIS T cellsPhase 1 ClinicalAeon Therapeutics (Beijing) Co LtdLiver Neoplasms; Carcinoma, Hepatocellular
Details
CPU-118CPU-118Phase 1 ClinicalChina Pharmaceutical University, Nanjing Qinling Pharmaceutical Technology Co LtdLiver Neoplasms; Solid tumours; Neoplasms
Details
  • Product List
  • Clinical Drug Information